Janux Therapeutics, Inc. (JANX)

NGM – Real Time Price. Currency in USD

14.41

+0.18 (1.26%)

At close: May 12, 2026, 4:00 PM EDT

14.10

-0.31 (-2.15%)

Pre-market: May 13, 2026, 6:37 AM EDT

08.05.2026

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.

07.05.2026

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr.

07.05.2026

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

04.05.2026

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation.

27.04.2026

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.

16.04.2026

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tumor-activated technology pl.

02.04.2026

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

27.04.2026

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

16.04.2026

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tumor-activated technology pl.

01.04.2026

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expr.

Janux Therapeutics, Inc. (JANX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

Videos

No Data

Press releases

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

Videos

No Data

Press releases

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Search stocks

Janux Therapeutics, Inc. (JANX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

Videos

No Data

Press releases

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

Videos

No Data

Press releases

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment